Adlumiz (anamorelin)
- Region
- 🇪🇺 EU
- Active substance
- anamorelin
- Company
- Helsinn Birex Pharmaceuticals Ltd.
- Status
- Refused
- Therapeutic area
- Cachexia; Anorexia; Carcinoma, Non-Small-Cell Lung
- CHMP opinion
- Thu 14 Sep 2017
- Application
- EMEA/H/C/003847
- ATC
- V03
- Official record
- www.ema.europa.eu
Indication
Treatment of anorexia, cachexia or unintended weight loss in adult patients with non-small cell lung cancer (NSCLC)
Regulatory milestones
No milestones recorded in the last year.
Follow Adlumiz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.